Compare

Aura Biosciences, Inc. vs SAB Biotherapeutics, Inc. vs Sutro Biopharma, Inc. vs Cabaletta Bio, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Aura Biosciences, Inc. AURA	SAB Biotherapeutics, Inc. SABSRevenue covers only part of its income (partial revenue)	Sutro Biopharma, Inc. STRO	Cabaletta Bio, Inc. CABA
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	$102.48M	n/a
Revenue growth (YoY)	n/a	n/a	+65.2%	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	-154.5%	n/a
Net margin	n/a	n/a	-186.5%	n/a
Net income	-$106.19M	$13.27M	-$191.09M	-$167.86M
EPS (Diluted)	-$1.76	-$0.79	-$22.49	-$2.10
Operating cash flow	-$84.74M	-$44.78M	-$177.23M	-$131.08M
Free cash flow	-$85.19M	-$45.71M	n/a	-$132.31M
Cash & equivalents	$59.52M	$10.50M	$58.13M	$82.98M
Total assets	$169.43M	$172.81M	$173.83M	$165.08M
Total liabilities	$32.52M	$21.32M	$306.28M	$53.03M
Shareholders' equity	$136.91M	$151.49M	-$132.45M	$112.05M
Return on year-end equity	-77.6%	8.8%	n/a	-149.8%
Shares outstanding	63.59M	47.61M	8.58M	100.48M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Aura Biosciences, Inc.	SAB Biotherapeutics, Inc.	Sutro Biopharma, Inc.	Cabaletta Bio, Inc.
Latest	n/a	n/a	$102.48M Ended 2025-12-31	n/a
1 year earlier	n/a	n/a	$62.04M Ended 2024-12-31	n/a
2 years earlier	n/a	n/a	$153.73M Ended 2023-12-31	n/a
3 years earlier	n/a	n/a	$67.77M Ended 2022-12-31	n/a
4 years earlier	n/a	n/a	$61.88M Ended 2021-12-31	n/a